- Details
- Zach Klaassen hosts a discussion with Fred Saad about the ARASENS data and its transformative impact on prostate cancer treatment. This conversation primarily explores the correlation between a rapid, deep, and durable PSA response and excellent patient outcomes. Dr. Saad underlines the biological significance of a decline in PSA, noting how patients who achieve undetectable PSA levels significant...
|
- Details
- Alicia Morgans interviews Matthew Smith about the ARASENS Study and its implications for patients focusing on the study's secondary endpoints, including time to pain progression and skeletal-related events, which are crucial for understanding patient well-being. He emphasizes that the study included a diverse range of patients with varying disease characteristics, and the overall survival benefit...
|
- Details
- Alicia Morgans and Karim Fizazi discuss the ARASENS data and how it relates to whether patients with high-volume or low-volume metastatic castration-sensitive disease should be treated differently with systemic treatments. They explain that while historically, CHAARTED showed benefits in high-volume but not low-volume disease, STAMPEDE showed benefits for all patients regardless of volume. The rec...
|
- Details
- Matthew Smith joins Alicia Morgans to discuss the post hoc analysis of the ARASENS study reporting the impact of disease burden and risk on efficacy and safety outcomes. The positive findings from the ARASENS study showed a significant improvement in overall survival, and those results supported the regulatory approval of darolutamide as part of triplet therapy in men with metastatic hormone-sensi...
|
- Details
- In this UroToday Journal Club discussion, Zach Klaassen analyzes the Journal of Clinical Oncology publication, "Darolutamide Plus ADT and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial." The ARASENS trial, a multicenter, randomized, double-blind, placebo-controlled Phase III study across 23 countries, assesses the combi...
|
- Details
- Alicia Morgans and Karim Fizazi discuss quality of life and patient-relevant endpoints with darolutamide in the phase 3 ARASENS study and which patient populations benefit most from this data. Dr Fizazi also details the P6 platform. P6 is for all patients with metastatic castration-sensitive disease. There are different phase three trials called P6. Drs Morgans and Fizazi discuss the P6 vulnerable...
|
- Details
- Alicia Morgans is joined by Neal Shore, who provides his perspective on the phase 3 ARASENS data for patients with metastatic hormone-sensitive prostate cancer, which demonstrates the superiority in terms of survival and numerous other secondary endpoints of triplet versus doublet therapy. In ARASENS, darolutamide + androgen-deprivation therapy (ADT) + docetaxel significantly reduced risk of death...
|
- Details
- Neal Shore joins Alicia Morgans in discussing the approval of NUBEQA® (darolutamide) in the metastatic hormone-sensitive setting in combination with docetaxel on ADT. Drs. Shore and Morgans speak about the clinical implications of this approval from a urologist's perspective. The approval was based on the overall survival data Matthew Smith presented at ASCO GU 2022 and the 32% reduction in mortal...
|
- Details
- In a conversation with Alicia Morgans, Professor Bertrand Tombal provides a synopsis of metastatic subtypes in the ARASENS trial outcomes. The ARASENS trial investigated the benefit of darolutamide by comparing ADT plus docetaxel and darolutamide versus a placebo group. Tombal and Morgans wrap up the conversation by acknowledging the pragmatic and effective treatment recommendations that resulted...
|
- Details
- Drs Charles Ryan and Alicia Morgans discuss the approval of NUBEQA® (darolutamide) tablets, for oral use for metastatic hormone-sensitive prostate cancer (mHSPC). The FDA has approved darolutamide in combination with docetaxel for adult patients with mHSPC. This regulatory decision is based on findings from the phase 3 ARASENS trial. ARASENS is a randomized phase 3 trial of darolutamide versus pla...
|
